Capstone Completes Acquisition of Canadian Stone Industries

Capstone Therapeutics ( (CAPS) ) just unveiled an update.

On December 1, 2025, Capstone Holding Corp. completed the acquisition of Canadian Stone Industries, a distributor with $15 million in annual revenue, which expands Capstone’s North American footprint and strengthens its brand portfolio. This acquisition is expected to immediately increase revenue and EBITDA, advancing Capstone towards its $100 million revenue target for early 2026, and reflects the company’s strategy of acquiring high-quality businesses to enhance its market position.

The most recent analyst rating on (CAPS) stock is a Hold with a $0.83 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.

Spark’s Take on CAPS Stock

According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.

Capstone Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, negative equity, and ongoing losses. Technical analysis suggests bearish momentum, with the stock trading below key moving averages. Valuation metrics are unattractive due to a negative P/E ratio and lack of dividend yield, further weighing on the stock’s appeal.

To see Spark’s full report on CAPS stock, click here.

More about Capstone Therapeutics

Capstone Holding Corp. (NASDAQ: CAPS) is a diversified platform of building products businesses focused on distribution, brand ownership, and acquisition. Through its Instone subsidiary, Capstone serves 32 U.S. states, offering proprietary stone veneer, hardscape materials, and modular masonry systems. The company’s strategy combines disciplined M&A, operational efficiency, and a growing portfolio of owned brands to build a scalable and durable platform.

Average Trading Volume: 896,903

Technical Sentiment Signal: Sell

Current Market Cap: $7.18M

Learn more about CAPS stock on TipRanks’ Stock Analysis page.